What to do with non-responders to CGRP(r) monoclonal antibodies: switch to another or move to gepants?

Marta Waliszewska-Prosół; Doga Vuralli; Paolo Martelletti

doi:10.1186/s10194-023-01698-8

The Journal of Headache and Pain (Dec 2023)

What to do with non-responders to CGRP(r) monoclonal antibodies: switch to another or move to gepants?

Marta Waliszewska-Prosół,
Doga Vuralli,
Paolo Martelletti

Affiliations

Marta Waliszewska-Prosół: Department of Neurology, Wrocław Medical University
Doga Vuralli: Department of Neurology and Algology, Neuroscience and Neurotechnology Center of Excellence (NÖROM), Faculty of Medicine, Neuropsychiatry Center, Gazi University
Paolo Martelletti: School of Health Sciences, UnitelmaSapienza University of Rome

DOI: https://doi.org/10.1186/s10194-023-01698-8
Journal volume & issue: Vol. 24, no. 1
pp. 1 – 5

Abstract

Read online

Abstract In this editorial we aim to provide potential therapeutic options in patients who do not benefit from treatment with CGRP(r) monoclonal antibodies. Based on current real-life studies and analysis of practical and economic aspects, we will analyze the potential benefits of changing CGRP-targeted treatment.

Published in The Journal of Headache and Pain

ISSN: 1129-2369 (Print); 1129-2377 (Online)
Publisher: BMC
Country of publisher: United Kingdom
LCC subjects: Medicine
Website: https://thejournalofheadacheandpain.biomedcentral.com/

About the journal

Abstract

Keywords